Таргетная терапия гормонорезистентного рака предстательной железы

Автор: Чернышев И.В., Жернов А.А., Перепечин Д.В.

Журнал: Экспериментальная и клиническая урология @ecuro

Рубрика: Онкоурология

Статья в выпуске: 1, 2012 года.

Бесплатный доступ

Гормонорезистентный рак предстательной железы, таргентная терапия, препараты, алгоритм лечения

Короткий адрес: https://sciup.org/142188289

IDR: 142188289

Список литературы Таргетная терапия гормонорезистентного рака предстательной железы

Yagoda A., Petrilak D. Cytotoxic chemotherapy for advanced hormone resistana prostate cancer//Cancer. 1993. Vol. 71. P. 1098-1109.
Abrahamsson P.A. Intermittent androgen blockade. Too good to be true?//Scand J Urol Nephrol Suppl. 1999. Vol. 203. P. 45-49.
Small E.J., Vogelzang N.J. Second-line hormone therapy for advanced prostate cancer: a shifting paradigm//J Clin Oncol. 1997. Vol. 15. P. 382-388.
Loriot Y., Massard C., Gross-Goupil M., Di Palma M., Escudier B., Bossi A., Fizazi K. Combining carboplatin and etoposide in docetaxelpretreated patients with castration-resistant prostate cancer: a prospective study evaluating also neuroendocrine features//Annals of Oncology. 2009. Vol. 20. P. 703-708.
Rosenberg J.E., Weinberg V., Kelly W.K., Michaelson D., Hussain M.H., Wilding G., Gross M., Hutcheon D., Small E.J. Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients: randomized phase 2 study of ixabepilone or mitoxantrone and prednisone//Cancer. 2007. Vol. 110. № 3. P. 556563.
Ross R.W., Beer T.M., Jacobus S., Bubley G.J., Taplin M.E, Ryan C.W., Huang J., Oh W.K.; Prostate Cancer Clinical Trials Consortium. A phase II trial of carboplatin plus docetaxel in hormone-refractory prostate cancer patients who have refractory after docetaxel chemotherapy.//Cancer. 2008. Vol. 112. № 3. P. 521-526.
Sternberg C.N., Petrylak D., Witjes F., Ferrero J., Eymard J., Falcon S., Chatta K., Vaughn D., Berry W., Sartor O. Satraplatin demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial//J Clin Oncology. 2007. ASCO Annual Meeting Proceedings Part I. Vol. 25. № 18S. Abstr. 5019.
Eymard J., Oudard S., Gravis G. et al. Second-line chemotherapy with docetaxel (D) in men treated with docetaxel-based regimen for metastatic hormonerefractory prostate cancer (mHRPC).//ASCO Prostate Cancer Symp 2007. Abstr 249.
Berthold D.R., Pond G., de Wit R., Eisenberger M., Tannock I.F.; TAX 327. Investigators. Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.//Ann Oncol. 2008. Vol. 19. № 10. P. 1749-1753.
Nakabayashi M., Ling J., Xie W., Regan M.M., Oh W.K. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone-refractory prostate cancer//Cancer J. 2007. Vol. 13. № 2. P. 125-129.
Michels J., Montemurro T., Murray N., Kollmannsberger C., Nguyen Chi K. First and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer//Cancer. 2006. Vol. 106. № 5. P. 1041-1046.
Oh W.K., Manola J., Babcic V., Harnam N., Kantoff P.W. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes.//Urology. 2006. Vol. 67. № 6. P. 1235-1240.
Tannock I.F., Osoba D., Stockler M.R., Ernst D.S., Neville A.J., Moore M.J., Armitage G.R., Wilson J.J., Venner P.M., Coppin C.M., Murphy K.C. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.//J Clin Oncol. 1996. Vol. 14. № 6. P. 1756-1764.
Hartley-Asp B., Natale R.B., Dreicer R., Falcon S., Ricardez A., Redfern C. et al. Phase II study of weekly intravenous estramustine phosphate 2.000 mg/m2 in patients with hormone-refractory prostate cancer//Proc Am Soc Clin Oncol. 2001. 20. Abstr 183.
Morote J., Lopez-Pacios M.A., Ahmad A., Vila J., De Torres J.A. Treatment of hormone-refractory prostate cancer with estramustine phosphate.//Actas Urol Esp. 1991. Vol. 15, N 5. P. 421-424.
Hudes G., Einhorn L., Ross E., Balsham A., Loehrer P., Ramsey H., Sprandio J., Entmacher M., Dugan W., Ansari R., Monaco F., Hanna M., Roth B.L. Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormonorrefractory prostate cancer: a Hoosier Oncology Group and Fox Chase Network phase III trial//J Clin Oncol. 1999. Vol. 17. № 10. P. 3160-3166.
Sweeny C.J., Monaco F.J., Jung S.H., Wasielewsky M.Y., Picus J., Ansar R.H. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in the hormone-refractory prostate cancer.//Ann Oncol. 2002. Vol. 13. № 3. P. 435-440.
Huguet Perez J., Maroto Rey P., Palou Redorta J., Villavicencio Mavrich H. Hormone-refractory prostate cancer. Changes in therapeutic strategies since the utility of chemotherapy.//Actas Urol Esp. 2006. Vol. 30. № 2. 123-133.
Yap R., Veliceasa D., Emmenegger U., Kerbel R.S., McKay L.M., Henkin J., Volpert O.V. Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy//Clin Cancer Res. 2005. Vol. 11. № 18. P. 6678-6685.
Lord R., Nair S., Schache A., Spicer J., Somaihah N., Khoo V., Pandha H. Low dose metronomic oral cyclophosphamide for hormone resistant prostate cancer: a phase II study//J Urol. 2007. Vol.177. № 6. P. 2136-2140.
Aragon-Ching J.B., Dahut W.L. About tyrosine kinase inhibitors (TKIs) in prostate cancer: where do we go from here?//Ann Oncol. 2010. Vol. 21, № 1. P. 183-184.
Attard G., Sarker D., Reid A., Molife R., Parker C., Bono de J.S. Improving the outcome of patients with castration-resistant prostate cancer through rational drug development//Br J Cancer. 2006. Vol. 95. № 7. P. 767-774.
Ortholan C., Durivault J., Hannoun-Levi J.M., Guyot M., Bourcier C., Ambrosetti D., Safe S., Pagès G. Bevacizumab/docetaxel association is more efficient than docetaxel alone in reducing breast and prostate cancer cell growth: A new paradigm for understanding the therapeutic effect of combined treatment.//Eur J Cancer. 2010. Vol. 46. № 16. P. 3022-3036.
Mitchell S.A., Danca M.D., Blomgren P.A., Darrow J.W., Currie K.S., Kropf J.E., Lee S.H., Gallion S.L., Xiong J.M., Pippin D.A., DeSimone R.W., Brittelli D.R., Eustice D.C., Bourret A., Hill-Drzewi M., Maciejewski P.M., Elkin L.L. Imidazo [1,2-a] pyrazine diaryl ureas: inhibitors of the receptor tyrosine kinase EphB4.//Bioorg Med Chem Lett. 2009. Volo. 19, N 24. P. 6991-6995.
Singh R.P., Sharma G., Mallikarjuna G.U., Dhanalakshmi S., Agarwal C., Agarwal R. In vivo suppression of hormonerefractory prostate cancer growth by inositol hexaphosphate: induction of insulinlike growth factor binding protein-3 and inhibition of vascular endothelial growth factor.//Clin Cancer Res. 2004. Vol. 10. № 1. Pt 1. P. 244-250.
Takei Y., Kadomatsu K., Yuzawa Y., Matsuo S., Muramatsu T. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics.//Cancer Res. 2004. Vol. 64. № 10. P. 3365-3370.
Fox W.D., Higgins B., Maiese K.M., Drobnjak M., Cordon-Cardo C., Scher H.I., Agus D.B. Antibody to vascular endothelial growth factor slows growth of an androgen-independent xenograft model of prostate cancer.//Clin Cancer Res. 2002. Vol. 8, № 10. P. 3226-3231.
Kohli M., Kaushal V., Spencer H.J., Mehta P. Prospective study of circulating angiogenic markers in prostate-specific antigen (PSA)-stable and PSAprogressive hormone-sensitive advanced prostate cancer.//Urology. 2003. Vol. 61. P. 765-769.
Shariat S.F., Anwuri V.A., Lamb D.J., Shah N.V., Wheeler T.M., Slawin K.M. Association of preoperative plasma levels of vascular endothelial growth factor and soluble vascular cell adhesion molecule-1 with lymph node status and biochemical progression after radical prostatectomy//J Clin Oncol. 2004. Vol. 22, № 9. P. 1655-1663.
George D.J., Regan M.M., Oh W.K., Tay M.H., Manola J., Decalo N., Duggan S., Dewolf W.C., Kantoff P.W., Bubley G.J. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in in patients with prostate cancer//Urology. 2004. Vol. 63. № 2. P. 327-332.
Mendel D.B., Laird, A.D., Xin X., Louie S.G., Christensen J.G., Li G., Schreck R.E., Abrams T.J., Ngai T.J., Lee L.B., Murray L.J., Carver J., Chan E., Moss K.G., Haznedar J.O., Sukbuntherng J., Blake R.A., Sun L., Tang C., Miller T., Shirazian S., McMahon G., Cherrington J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.//Clin Cancer Res. 2003. Vol. 9. № 1. P. 327-337.
O'Farrell A.M., Abrams T.J., Yuen H.A., Ngai T.J., Louie S.G., Yee K.W., Wong L.M., Hong W., Lee L.B., Town A., Smolich B.D., Manning W.C., Murray L.J., Heinrich M.C., Cherrington J.M. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo//Blood. 2003. Vol. 101. № 9. P. 3597-3605.
Fokt R.M., Templeton A., Gillessen S., Ohlschlegel C., Schmid H.P. Prostatic metastasis of renal cell carcinoma successfully treated with sunitinib.//Urol Int. 2009. Vol. 83. № 1. P. 122-124.
Cumashi A., Tinari N., Rossi C., Lattanzio R., Natoli C., Piantelli M., Iacobelli S. Cancer Lett. Sunitinib malate (SU-11248) alone or in combination with low-dose docetaxel inhibits the growth of DU-145 prostate cancer xenografts//Cancer Lett. 2008. Vol. 270. № 2. P. 229-233.
Dror Michaelson M., Regan M.M., Oh W.K., Kaufman D.S., Olivier K., Michaelson S.Z., Spicer B., Gurski C., Kantoff P.W., Smith M.R. Phase II study of sunitinib in men with advanced prostate cancer.//Ann Oncol. 2009. Vol. 20, № 5. P. 913-920.
Sonpavde G., Periman P.O., Bernold D., Weckstein D., Fleming M.T., Galsky M.D., Berry W.R., Zhan F., Boehm K.A., Asmar L., Hutson T.E. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy.//Ann Oncol. 2010. Vol. 21. № 2. P. 319-324.
http://www.clinicaltrials.gov/ct2/show/NCT00945477?term=pazopanib&rank=21
http://www.clinicaltrials.gov/ct2/show/NCT00454571?term=pazopanib&rank=86
http://www.clinicaltrials.gov/ct2/show/NCT01385228?term=pazopanib&rank=3

Еще

Статья